Impact of Vitamin D on Chronic Kidney Diseases in Non-Dialysis Patients: A Meta-Analysis of Randomized Controlled Trials

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Xu, Lijuan ^a   Wan, Xuesi ^a   Huang, Zhimin ^a   Zeng, Fangfang ^b   Wei, Guohong ^a   Fang, Donghong ^a   Deng, Wanping ^a   Li, Yanbing ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; CALCITRIOL; COLECALCIFEROL; DOXERCALCIFEROL; ERGOCALCIFEROL; PARICALCITOL; PLACEBO; VITAMIN D;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ACUTE KIDNEY FAILURE; ARTHRALGIA; ARTICLE; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; CONSTIPATION; COUGHING; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; EDEMA; ERECTILE DYSFUNCTION; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; GOUT; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERKALEMIA; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER DYSFUNCTION; MALABSORPTION; MALAISE; META ANALYSIS; MUSCLE SPASM; MYALGIA; NEPHROLITHIASIS; NEUROMUSCULAR DISEASE; PAIN; PARONYCHIA; PNEUMONIA; PROTEINURIA; PSEUDOGOUT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; SIDE EFFECT; STOMACH PARESIS; SWEATING; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VITAMIN SUPPLEMENTATION; ADULT; AGED; ANALOGS AND DERIVATIVES; BIBLIOGRAPHIC DATABASE; CHEMICALLY INDUCED; CHRONIC KIDNEY FAILURE; DIET SUPPLEMENTATION; DIET THERAPY; DRUG EFFECTS; MIDDLE AGED; PATHOPHYSIOLOGY;

ADULT; AGED; DATABASES, BIBLIOGRAPHIC; DIETARY SUPPLEMENTS; GLOMERULAR FILTRATION RATE; HUMANS; HYPERCALCEMIA; MIDDLE AGED; PROTEINURIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY, CHRONIC; VITAMIN D;

EID: 84876528916     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061387     Document Type: Article

References (43)

1. Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, et al. (2012) United States Renal Data System 2011 Annual Data Report. Am J Kidney Dis 59 (1 Suppl 1): A7, e1-420.
2. De Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, et al. (2004) Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110: 921-927.
3. Knobler H, Zornitzki T, Vered S, Oettinger M, Levy R, et al. (2004) Reduced glomerular filtration rate in asymptomatic diabetic patients: predictor of increased risk for cardiac events independent of albuminuria. J Am Coll Cardiol 44: 2142-2148.
4. Salles GF, Cardoso CR, Pereira VS, Fiszman R, Muxfeldt ES, (2011) Prognostic significance of a reduced glomerular filtration rate and interaction with microalbuminuria in resistant hypertension: a cohort study. J Hypertens 29: 2014-2023.
5. Zhang Y, Deb DK, Kong J, Ning G, Wang Y, et al. (2009) Long-term therapeutic effect of vitamin D analog doxercalciferol on diabetic nephropathy: strong synergism with AT1 receptor antagonist. Am J Physiol Renal Physiol 297: F791-801.
6. De Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, et al. (2010) Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376: 1543-1551.
7. Slatopolsky E, Finch J, Brown A, (2003) New vitamin D analogs. Kidney Int 63 (Suppl 85): S83-87.
8. Mehrotra R, Kermah D, Budoff M, Salusky IB, Mao SS, et al. (2008) Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol 3: 1144-1151.
9. LaClair RE, Hellman RN, Karp SL, Kraus M, Ofner S, et al. (2005) Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 45: 1026-33.
10. Follmann D, Elliott P, Suh I, Cutler J, (1992) Variance imputation for overviews of clinical trials with continuous response. J Clin Epidemiol 45: 769-773.
11. Nordal KP, Eilif D, (1988) Low Dose Calcitriol Versus Placebo in Patients with Predialysis Chronic Renal Failure. J Clin Endocrinol Metab 67: 929-936.
12. Hamdy NA, Kanis JA, Beneton MN, Brown CB, Juttmann JR, et al. (1995) Effect of alfacalcidol on natural course ofrenal bone disease in mild to moderate renal failure. BMJ 310: 358-363.
13. Coburn JW, Maung HM, Elangovan L, Germain MJ, Lindberg JS, et al. (2004) Doxercalciferol Safely Suppresses PTH Levels in PatientsWith Secondary Hyperparathyroidism Associated With Chronic Kidney Disease Stages 3 and 4. Am J Kidney Dis 43: 877-890.
14. Rix M, Eskildsen P, Olgaard K, (2004) Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Nephrol Dial Transplant 19: 870-876.
15. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, et al. (2005) Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney International 68: 2823-2828.
16. Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, et al. (2006) Paricalcitol Capsule for the Treatment of Secondary Hyperparathyroidism in Stages 3 and 4 CKD. Am J Kidney Dis 47: 263-276.
17. Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, et al. (2008) Paricalcitol Reduces Albuminuria and Inflammation in Chronic Kidney Disease. Hypertension 52: 249-255.
18. Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, et al. (2009) Oral Paricalcitol in the Treatment of Patients With CKD and Proteinuria: A Randomized Trial. Am J Kidney Dis 54: 647-652.
19. Rucker D, Tonelli M, Coles MG, Yoo S, Young K, et al. (2009) Vitamin D insufficiency and treatment with oral vitamin D3 in northern-dwelling patients with chronic kidney disease. J Nephrol 22: 75-82.
20. Liu LJ, Lv JC, Shi SF, Chen YQ, Zhang H, et al. (2012) Oral Calcitriol for Reduction of Proteinuria in Patients With IgA Nephropathy: A Randomized Controlled Trial. Am J Kidney Dis 59: 67-74.
21. Basturk T, Unsal A, Ulas T, (2011) Effect of Cholecalciferol on Parathyroid Hormone and Vitamin D Levels in Chronic Kidney Disease. Minerva Urol Nefrol 63: 287-292.
22. Alvarez JA, Law J, Coakley KE, Zughaier SM, Hao L, et al. (2012) High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial. Am J Clin Nutr 96: 672-679.
23. Krairittichai U, Mahannopkul R, Bunnag S, (2012) An Open Label, Randomized Controlled Study of Oral Calcitriol for the Treatment of Proteinuria in Patients with Diabetic Kidney Disease. J Med Assoc Thai 95: S41-S47.
24. Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, (2012) Vitamin D Therapy and Cardiac Structure and Function in Patients With Chronic Kidney Disease: The PRIMO Randomized Controlled Trial. JAMA 307: 674-684.
25. Shroff R, Wan M, Gullett A, Ledermann S, Shute R, et al. (2012) Ergocalciferol Supplementation in Children with CKD Delays the Onset of Secondary Hyperparathyroidism: A Randomized Trial. Clin J Am Soc Nephrol 7: 216-223.
26. Moe SM, Saifullah A, LaClair RE, Usman SA, Yu Z, (2010) A Randomized Trial of Cholecalciferol versus Doxercalciferol for Lowering Parathyroid Hormone in Chronic Kidney Disease. Clin J Am Soc Nephrol 5: 299-306.
27. Kovesdy CP, Lu JL, Malakauskas SM, Andress DL, Kalantar-Zadeh K, et al. (2012) Paricalcitol Versus Ergocalciferol for Secondary Hyperparathyroidism in CKD Stages 3 and 4: A Randomized Controlled Trial. Am J Kidney Dis 59: 58-66.
28. Tian J, Liu Y, Williams LA, de Zeeuw D, (2007) Potential role of active vitamin D in retarding the progression of chronic kidney disease. Nephrol Dial Transplant 22: 321-328.
29. De Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS, (2007) 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 50: 69-77.
30. Wang Y, Zhou J, Minto AW, Hack BK, Alexander JJ, et al. (2006) Altered vitamin D metabolism in type II diabetic mouse glomeruli may provide protection from diabetic nephropathy. Kidney Int 70: 882-891.
31. Deb DK, Chen Y, Zhang Z, Zhang Y, Szeto FL, et al. (2009) 1,25-Dihydroxyvitamin D3 suppresses high glucose-induced angiotensinogen expression in kidney cells by blocking the NF-κB pathway. Am J Physiol Renal Physiol 296: F1212-F1218.
32. Zhang Z, Sun L, Wang Y, Ning G, Minto AW, et al. (2008) Renoprotective role of the vitamin D receptor in diabetic nephropathy. Kidney Int 73: 163-71.
33. Takano Y, Yamauchi K, Hiramatsu N, Kasai A, Hayakawa K, et al. (2007) Recovery and maintenance of nephrin expression in cultured podocytes and identification of HGF as a repressor of nephrin. Am J Physiol Renal Physiol 292: F1573-F1582.
34. Christiansen C, Rødbro P, Christensen MS, Hartnack B, Transbøl I, (1978) Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol. Lancet 2: 700-703.
35. Thomas MC, MacIsaac RJ, Tsalamandris C, Power D, Jerums G, (2009) Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment co-existing with NIDDM [NEFRON] 11). Diabetes Care 32: 1497-1502.
36. Molitch ME, Steffes M, Sun W, Rutledge B, Cleary P, et al. (2010) Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 33: 1536-1543.
37. Kramer CK, Leitão CB, Pinto LC, Silveiro SP, Gross JL, et al. (2007) Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria. Diabetes Care 30: 1998-2000.
38. De Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, et al. (2004) Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney International 65: 2309-2320.
39. Remuzzi G, Chiurchiu C, Ruggenenti P, (2004) Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN). Kidney Int Suppl 92: S90-96.
40. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, et al. (1999) Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354: 359-364.
41. Remuzzi G, Chiurchiu C, Ruggenenti P, (2004) Proteinuria predicting outcome in renal disease: nondiabetic nephropathies (REIN). Kidney Int Suppl 92: S90-96.
42. Hunsicker LG, Atkins RC, Lewis JB, Braden G, de Crespigny PJ, et al. (2004) Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. Kidney Int Suppl 66: S99-101.
43. Palmer SC, McGregor DO, Macaskill P, Craig JC, Elder GJ, et al. (2007) Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 147: 840-853.